Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Tapentadol Stories

2011-04-14 07:31:00

SYDNEY, Australia and BEDMINSTER, N.J., April 14, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029. This patent covers a proprietary dosing algorithm for converting patients from intravenous opioid administration to orally administered MoxDuo IR, thereby more effectively and safely managing acute pain following surgery....

2011-04-04 07:01:00

NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced additional data that showed that overweight and obese patients treated with Contrave® (naltrexone sustained release (SR)/bupropion SR) maintained normal 24-hour circadian patterns over one year of treatment. These data were from the ambulatory blood pressure monitoring (ABPM) sub-study of the COR-II trial that also showed weight loss and improvements in...

2011-03-30 07:00:00

SHELTON, Conn., March 30, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the appointment of James B. Jones, M.D., Pharm.D., to the position of Chief Medical Officer. In this role, Dr. Jones will oversee the ongoing clinical development of Cara's lead drug candidate, CR845, a novel, peripherally-restricted kappa opioid agonist, which is currently in Phase 2 development for treatment of post-operative pain. "We are delighted to add someone of Jim's clinical background and drug...

2011-03-25 05:00:00

NATIONAL HARBOR, Md., March 25, 2011 /PRNewswire-USNewswire/ -- Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period. "Butrans is a new treatment for chronic pain that was...

2011-03-15 11:06:00

SAN FRANCISCO, March 15, 2011 /PRNewswire/ -- AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to investigate the safety and efficacy of NKTR-118 as a medicine to relieve opioid induced constipation, a common side effect of prescription opioids when used for chronic...

2011-03-11 12:29:00

TALLAHASSEE, Fla., March 11, 2011 /PRNewswire/ -- The Florida Society of Pain Management Providers (www.Flspmp.org) releases the latest facts on Oxycodone and Hydrocodone use in the United States. Until now these statistics were not readily available to the public or media. Oxycodone dispensed in U.S. 2009 by state (per 100,000 population) ------------------------------------------------------------------ Methodology: Sources: DEA 2009 ARCOS report, US Census and FDA....

2011-02-23 00:00:42

Company Successfully Completes Third Pivotal MoxDuo® Phase 3 Study Sydney, Australia and Bedminster, New Jersey (Vocus/PRWEB) February 21, 2011 QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo. Designed to evaluate the analgesic efficacy and...

b73785a5450a63b90b80866b5fe67e911
2011-02-17 06:20:00

Scientists studying the benefits of pain medications said Wednesday that people who do not believe their pain drugs will work may actually reduce or even rescind the effectiveness of those drugs. Researchers from Britain and Germany used brain scans to examine how a person's feelings and past experiences can influence how medicines work in their bodies, and discovered that a powerful painkilling medication with a true biological effect can appear not to be working if a patient has been...

2011-02-15 15:07:00

NASHVILLE, Tenn., Feb. 15, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data from a clinical trial evaluating the pharmacokinetics, safety and tolerability of a rapid infusion of Caldolor® (ibuprofen) Injection compared to oral ibuprofen. The study, which was published in the January issue of American Journal of Health-System Pharmacy, demonstrated that the maximum plasma concentration (Cmax) of IV ibuprofen when...

2011-01-28 07:30:00

RARITAN, N.J., Jan. 28, 2011 /PRNewswire/ -- New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication. This phase III study, which evaluates the safety and efficacy of tapentadol ER against placebo for relieving moderate to severe chronic pain associated with diabetic peripheral neuropathy (DPN), is...